Re: selective inhibition of Her2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.
Shailendra
S
Kapoor
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D019888:Nelfinavir / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D017320:HIV Protease Inhibitors; D018841:HSP90 Heat-Shock Proteins; D019888:Nelfinavir; D018719:Erb-b2 Receptor Tyrosine Kinases